Using the industry peer median EV/Revenue multiple (trailing + forward), Aktis Oncology, Inc. (AKTS) has a fair value of $2.35 based on 7 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Aktis Oncology, Inc.AKTS | 960 | 143.7x | 57.2x |
| Vertex Pharmaceuticals Incorporated | 110,312 | 9.0x | 8.4x |
| Regeneron Pharmaceuticals, Inc. | 79,282 | 5.5x | 5.0x |
| argenx SE | 46,304 | 10.3x | 7.2x |
| Alnylam Pharmaceuticals, Inc. | 43,811 | 11.7x | 7.8x |
| Insmed Incorporated | 35,310 | 58.7x | 21.0x |
| United Therapeutics Corporation | 24,528 | 7.2x | 6.9x |
| Royalty Pharma plc | 20,273 | 12.0x | 8.8x |
| Industry Median | 10.3x | 7.8x | |
| (*) Revenue | 6 | 16 | |
| = Enterprise Value | 67 | 127 | |
| (-) Net Debt | -26 | -26 | |
| Equity Value | 93 | 154 | |
| (/) Outstanding shares | 53 | 53 | |
| Fair Price | $2 | $3 | |
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.